Dr. Andrew Muir joined Midven in 2004. He is a Director of the Company and Fund Principal of the UK Innovation & Science Seed Fund and the Early Advantage fund.
After an initial scientific career at Zeneca he went on to roles in research and business development at the medical device company Biocompatibles and then Vice President of Technology for a US start-up in disinfection of medical equipment.
He started his career in VC with the £4m per annum Invention and Innovation seed capital fund at NESTA (the National Endowment for Science Technology and the Arts). He has a degree and a PhD in Chemistry from the University of Oxford.
Andrew combines a strong scientific and technical grounding with a real commercial pragmatism developed from his operational roles.
Telephone 0121 710 1990
“Development and commercialisation of new technologies is key to the UK retaining its global competitiveness.”
. Cambridge and Newcastle, UK, 21st August 2019: Atelerix, pioneers in the storage and…
read more
Cell encapsulation for transport of cells and tissues at room temperature 9th May 2019 --…
read more
Software leader in the field of genomic data and bioinformatics analysis poised for growth 30…
read more
Oxford Space Systems (OSS) has successfully secured £1.2m in its second round fund raise from…
read more
Summary Creating smart textiles by adding conductivity to fabrics at any stage Pireta has developed…
read more
Insight From Light Cobalt Light Systems develops innovative instruments and technologies for non-invasive, rapid analysis…
read more
Summary Oxsensis is pioneering a “new breed” of highly accurate, highly stable optical sensors. Using…
read more
Andrew Muir, PhD, is a director at Midven, and leads the UK Innovation & Science…
read more
Creating a new technology company is an exciting time. It is an opportunity to get…
read more
